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AbstrACt
Introduction The major unmet need in multiple sclerosis 
(MS) is for neuroprotective therapies that can slow (or ideally 
stop) the rate of disease progression. The UK MS Society 
Clinical Trials Network (CTN) was initiated in 2007 with 
the purpose of developing a national, efficient, multiarm 
trial of repurposed drugs. Key underpinning work was 
commissioned by the CTN to inform the design, outcome 
selection and drug choice including animal models and a 
systematic review. This identified seven leading oral agents 
for repurposing as neuroprotective therapies in secondary 
progressive MS (SPMS). The purpose of the Multiple 
Sclerosis-Secondary Progressive Multi-Arm Randomisation 
Trial (MS-SMART) will be to evaluate the neuroprotective 
efficacy of three of these drugs, selected with distinct 
mechanistic actions and previous evidence of likely efficacy, 
against a common placebo arm. The interventions chosen 
were: amiloride (acid-sensing ion channel antagonist); 
fluoxetine (selective serotonin reuptake inhibitor) and riluzole 
(glutamate antagonist).
Methods and analysis Patients with progressing SPMS 
will be randomised 1:1:1:1 to amiloride, fluoxetine, 
riluzole or matched placebo and followed for 96 weeks. 
The primary outcome will be the percentage brain 
volume change (PBVC) between baseline and 96 weeks, 
derived from structural MR brain imaging data using 
the Structural Image Evaluation, using Normalisation, 
of Atrophy method. With a sample size of 90 per arm, 
this will give 90% power to detect a 40% reduction in 
PBVC in any active arm compared with placebo and 
80% power to detect a 35% reduction (analysing by 
analysis of covariance and with adjustment for multiple 
comparisons of three 1.67% two-sided tests), giving a 
5% overall two-sided significance level. MS-SMART is 
not powered to detect differences between the three 
active treatment arms. Allowing for a 20% dropout rate, 
110 patients per arm will be randomised. The study 
will take place at Neuroscience centres in England and 
Scotland.
Ethics and dissemination MS-SMART was approved by 
the Scotland A Research Ethics Committee on 13 January 
2013 (REC reference: 13/SS/0007). Results of the study will 
be submitted for publication in a peer-reviewed journal.
trial registration numbers NCT01910259; 2012-005394-
31; ISRCTN28440672.
strengths and limitations of this study
 ► The  Multiple Sclerosis -Secondary Progressive 
Multi-Arm Randomisation Trial (MS-SMART) will be 
the first multi-arm efficient trial design in progres-
sive multiple sclerosis.
 ► UK MS society developed the national trial with 
strong public patient involvement.
 ► It will test three active repurposed agents with 
distinct mechanistic profiles based on systematic 
review.
 ► The primary outcome in this phase IIb trial will be 
volumetric brain MRI.
 ► A definitive disability outcome phase III trial will be 
needed for any successful candidate drug identified 
from MS-SMART.
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IntroduCtIon 
Multiple sclerosis (MS) is a disease of the central nervous 
system estimated to affect >2.5 million people globally; it 
is the the most common non-traumatic cause of acquired 
disability for young adults in the industrialised world.1 2 Most 
people with MS (PwMS) experience two clinical phases 
reflecting distinct, but inter-related pathological processes: 
focal inflammation driving the relapsing-remitting phase 
(RRMS), whereas neurodegeneration represents the prin-
cipal substrate of secondary progression (SPMS).3 Conver-
sion to secondary progressive MS occurs at around 2%–5% 
per annum (typically 10–15 years into the disease trajec-
tory), and is characterised by accumulating and irrevers-
ible disability across a range of functions such as walking, 
balance, vision, cognition, continence and pain control.4 In 
contrast to the increasing number of effective anti-inflam-
matory disease-modifying treatments for relapsing-remit-
ting disease, the paucity of therapies for progressive disease 
represents a major unmet clinical need,5 although since this 
trial commenced, some success has now been seen for ocreli-
zumab in primary progressive MS6 and siponimod in SPMS.7 
Within the wider context of issues relevant to all drug devel-
opment programmes, such as high costs and the prolonged 
time from target selection to regulatory approval, the failure 
of therapeutic development for SPMS using conventional 
pipelines8 has led to interest in novel approaches such 
as ‘drug rescue’ (evaluating drugs at advanced stage of 
development but abandoned before approval) and ‘repur-
posing’ (evaluating drugs already approved for other indica-
tions),9 this offers the potential to reduce both the cost and 
time taken to achieve licensed approval status.10 As develop-
ment costs are brought within a range acceptable to public 
and third-sector funders, the opportunity for investigator-led 
phase II/III research increases.
Delivering a successful repositioned neuroprotective 
treatment for SPMS nevertheless represents a substantial 
challenge. The prior failure to develop such therapies likely 
reflects a combination of factors, which include the limited 
predictive value of existing animal models.11 12 Although 
such experimental systems capture aspects of the disease, 
they fail to replicate the complex and multifaceted pathobi-
ology that underpins neurodegeneration in SPMS including: 
microglial activation, chronic oxidative injury, accumula-
tion of mitochondrial damage in axons with imbalance of 
ionic homeostasis and age-related iron accumulation in the 
human brain.13 The relative importance of these processes, 
and the therapeutic value of targeting components in isola-
tion remains unclear.14 Given the highly complex patho-
biology of SPMS, an optimum strategy to select drugs for 
evaluation in repositioning trials has not yet been estab-
lished. The UK MS Society Clinical Trials Network was initi-
ated in 2007 with a core tenet to develop trials in progressive 
MS where success had been lacking. Key underpinning work 
was commissioned to improve trial design, examine available 
outcomes (interim and final) and systematically review the 
animal and human data on possible candidate drugs. Based 
on recognition of substantial mechanistic overlap between 
SPMS and other ‘classic’ neurodegenerative disorders such 
as Alzheimer’s disease,15 we performed a systematic review 
and meta-analysis of all published clinical and preclinical 
research investigating putative oral neuroprotective drugs 
in MS, Alzheimer’s disease, Huntington’s disease, amyo-
trophic lateral sclerosis and Parkinson’s disease. We identified 
seven agents as lead candidates for therapeutic evaluation.16 
These were ibudilast, riluzole, amiloride, pirfenidone, fluox-
etine, oxcarbazepine and the polyunsaturated fatty-acid 
class (linoleic acid, lipoic acid; omega-3 fatty acid, Max EPA 
oil). The initial choice was amiloride, riluzole and ibudilast, 
but due to drug supply issues, ibudilast was substituted with 
fluoxetine.
Testing neuroprotection in SPMS also presents several 
major challenges relating to trial design such as subject 
and disease heterogeneity, and the selection of relevant 
outcomes and end points.14 17 In particular, poor reliability 
and responsiveness for benchmark clinical outcomes such 
as the Expanded Disability Status Scale (EDSS) presents a 
substantial problem for phase III trials.18 Newer clinical 
disability scales such as the Multiple Sclerosis Functional 
Composite (MSFC) offer improved psychometric properties, 
and have recommended definitions for clinically meaningful 
change.19 However, the selection of relevant end points to 
evaluate clinically meaningful neuroprotection remains 
a matter of ongoing debate, with some advocating ‘hard’ 
definitions such as the composite ‘dead or dependent’.20 In 
contrast, MRI measures of brain tissue volume reduction over 
time (brain atrophy) provide both a biomarker of neurode-
generation and a surrogate outcome for disease progression 
with feasible sample size requirements to support proof-
of-concept evaluation at phase II.21 Neuroprotection in 
SPMS based on MR brain atrophy measurement has been 
successfully demonstrated in a recent placebo-controlled 
randomised controlled trial evaluating high-dose simvastatin 
(MS-STAT).22 The area has recently been comprehensively 
reviewed.23
Against this background, we set out to design a phase IIb 
multiarm randomised placebo-controlled trial (MS-SMART; 
NCT01910259) that would simultaneously evaluate three 
repurposed oral neuroprotective agents from our previously 
identified selection of lead candidates. MS-SMART tests 
the hypothesis that treatment with amiloride or riluzole or 
fluoxetine versus placebo reduces the rate of brain atrophy 
in SPMS. In this article, we describe in detail the trial design, 
rationale for the drug selection and all pre-specified anal-
yses. The trial has fully recruited and is in follow-up, with the 
last patient last visit occurring on 4th July 2018. This article 
refers to the current protocol (V.7, date 4 June 2018).
MEthods And AnAlysIs
trial objectives
The primary objective of MS-SMART is to establish 
whether amiloride or fluoxetine, or riluzole can slow the 
rate of brain volume loss in SPMS over 96 weeks, against 
placebo, using MRI-derived percentage brain volume 
change (PBVC). Secondary objectives are to: (i) estab-
lish that a multiarm trial strategy is an efficient way of 
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screening drugs in SPMS. (ii) Evaluate anti-inflammatory 
drug activity using the count of new and enlarging T2 
lesions. (iii) Examine for evidence of pseudo-atrophy by 
MRI. (iv) Examine for clinical efficacy as measured by clini-
cian (EDSS, MSFC, symbol digit modalities test [SDMT], 
Sloan low-contrast visual acuity [SLCVA] and relapse rate) 
and patient-reported outcomes (multiple sclerosis impact 
scale version two [MSIS29v2], multiple sclerosis walking 
scale version two [MSWSv2]), pain (numeric pain rating 
scale [NPRS], brief pain inventory [BPI], neuropathic 
pain scale [NPS]) and fatigue (neurological fatigue index 
[NFI]). (v) Collect basic health economic data based on 
the EuroQol five dimensions questionnaire (EQ-5D-5L). 
Exploratory objectives are to evaluate putative neuro-
protection by: (i) proportion of new and enlarging T2 
lesions at 24 weeks being persistently T1 hypointense at 
week 96; (ii) grey matter brain volume change. In certain 
centres (UCL/Edinburgh), further advanced metrics are 
measured (not described further here): MR spectroscopy, 
MR magnetisation transfer ratio, cervical cord imaging, 
optical coherence tomography and cerebrospinal fluid 
neurofilament levels.
overview of design
MS-SMART is a phase IIB multicentre, multiarm, double-
blind, randomised placebo-controlled trial that compares 
three oral repurposed candidate neuroprotective thera-
pies (amiloride 5 mg twice a day, fluoxetine 20 mg twice 
a day and riluzole 50 mg twice a day) against a shared 
placebo arm in people with SPMS. The primary end point 
is brain volume loss over 96 weeks as measured using 
MRI-derived PBVC. Four hundred and forty participants 
randomised in a 1:1:1:1 ratio. Participants will be evalu-
ated during nine study visits and a final telephone safety 
evaluation at week 100 (figure 1).
PArtICIPAnts, IntErvEntIons And outCoMEs
trial setting
MS-SMART will be conducted across 13 UK hospital 
research facilities in London, Edinburgh, Liverpool, 
Sheffield, Brighton, Truro, Oxford, Stoke-on-Trent, Plym-
outh, Newcastle, Leeds, Nottingham and Glasgow. All 
imaging acquisition will be performed in the local neuro-
imaging facility before being transferred to the central 
facility (Queen Square MS Centre) for central quality 
control and blinded analysis.
Eligibility criteria
Inclusion and exclusion criteria for MS-SMART are shown 
in table 1.
Ascertainment and recruitment
Potential participants will be identified through five 
routes. (i) Clinics run by principal investigators (PIs) or 
associated neurologists at participating sites. (ii) Clinics 
run at other MS centres/neuroscience/hospital centres 
set up as participant identification centres. (iii) Through 
existing MS research and other databases such as the Scot-
tish Health Research Register (SHARE, http://www. regis-
terforshare. org) that contain contact details of people 
who have consented to be contacted directly about rele-
vant research opportunities. (iv) By general practitioners 
(GPs) at routine appointments. (v) By self-referral from 
potential participants, in particular using the http://
Figure 1 Multiple Sclerosis-Secondary Progressive Multi-
Arm Randomisation Trial participant timeline.
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www. ms- smart. org/ website. All such referrals (or patient 
self-referrals) will require medical history records to 
confirm that they have MS as per usual clinical prac-
tice24–26 and any other relevant medical conditions.
Depending on the route of identification several 
processes to provide information and ‘prescreen’ for 
eligibility will be permissible. Candidate participants 
will be briefed in clinic about the study directly by a 
member of the clinical team; ‘prescreening’ to ensure 
that the people with MS will be likely to fulfil the general 
criteria to enter the trial and candidate participants will 
be given a patient information leaflet (PIL). Alterna-
tively, candidate participants will receive an initial tele-
phone contact from a member of the research team 
to explain the trial and ‘prescreen’. Potential partici-
pants will then be recontacted by the study team at an 
interval no less than 24 hours after receiving the PIL to 
ask if they wish to proceed to screening. If required and 
following documented permission from the potential 
participant, their neurologist/GP will also be contacted 
Table 1 Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial eligibility criteria (protocol V.7)
Inclusion criteria
 ► Confirmed diagnosis of SPMS. Steady progression rather 
than relapse must be the major cause of increasing 
disability in the preceding 2 years. Progression can be 
evident from either an increase of at least one point in 
EDSS or clinical documentation of increasing disability in 
patients notes.
 ► EDSS 4.0–6.5.
 ► Aged 25–65 inclusive.
 ► Women and men with partners of childbearing potential 
must be using an appropriate method of contraception to 
avoid any unlikely teratogenic effects of the three drugs 
from time of consent, to 6 weeks after treatment inclusive.
 ► Women must have a negative pregnancy test within 
7 days prior to the baseline visit unless not of childbearing 
potential (eg, have undergone a hysterectomy, bilateral 
tubal ligation or bilateral oophorectomy or they are 
postmenopausal).
 ► Willing and able to comply with the trial protocol (eg, can 
tolerate MRI and fulfils the requirements for MRI, eg, not 
fitted with pacemakers or permanent hearing aids), ability to 
understand and complete questionnaires.
 ► Written informed consent provided.
Exclusion criteria
 ► Pregnancy or breastfeeding patients.
 ► Baseline MRI scan not of adequate quality for analysis (eg, 
too much movement artefact).
 ► Significant organ comorbidity (eg, malignancy or renal or 
hepatic failure).
 ► Relapse within 3 months of baseline visit.
 ► Patients who have been treated with intravenous or oral 
steroids for an MS relapse/progression within 3 months of 
baseline visit (these patients can undergo future screening 
visits once the 3-month window has expired), patients on 
steroids for another medical condition may enter as long 
as the steroid prescription will be not for MS (relapse/
progression).
 ► Use of simvastatin at 80 mg dose within 3 months of 
baseline visit (lower doses of simvastatin and other statins 
are permissible).
 ► Commencement of fampridine within 6 months of baseline 
visit.
 ► Use of immunosuppressants (eg, azathioprine, 
methotrexate, ciclosporin) or first-generation disease-
modifying treatments (β-interferons, glatiramer) within 
6 months of baseline visit.
 ► Use of fingolimod, fumarate, teriflunomide, laquinimod or 
other experimental disease-modifying treatment (including 
research in an investigational medicinal product) within 
12 months of baseline visit.
 ► Use of mitoxantrone, natalizumab, alemtuzumab, 
daclizumab, if treated within 12 months of baseline visit.
 ► Primary progressive MS.
 ► Relapsing-remitting MS.
 ► Known hypersensitivity to the active substances and their 
excipients to any of the active drugs for this trial.
 ► Use of an SSRI within 6 months of the baseline visit.
 ► Current use of tamoxifen.
 ► Current use of herbal treatments containing St. John’s wort.
 ► Significant signs of depression.
 ► Patients with a history of bleeding disorders or currently on 
anticoagulants.
 ► Use of monoamine oxidase inhibitors, phenytoin, 
L-tryptophan and/or neuroleptic drugs within 6 months of 
the baseline visit.
 ► Use of lithium, chlorpropamide, triamterene and 
spironolactone within 6 months of the baseline visit.
 ► Current use of potassium supplements.
 ► Significant signs of depression bipolar disorder.
 ► A Beck Depression Index score of 19 or higher.
 ► Epilepsy/seizures.
 ► Receiving or previously received electroconvulsive therapy.
 ► Glaucoma.
 ► Routine screening blood values:
 – LFTs (ALT/AST, bilirubin, gamma-GT)>3x upper limit of 
normal of site reference ranges.
 – Potassium<2.8 mmol/L or >5.5 mmol/L.
 – Sodium<125 mmol/L.
 – Creatinine>130µmol/L.
 – WBCs<3×109/L.
 – Lymphocytes<0.8×109/L.
 – Neutrophil count<1.0×109/L.
 – Platelet count<90×109/L.
 – Haemoglobin<80 g/L.
ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; EDSS, Expanded Disability Status Scale; GT, glutamyl transferase; LFT, liver 
function test; MS, multiple sclerosis; SPMS, secondary progressive multiple sclerosis; SSRI, selective serotonin-reuptake inhibitor; WBC, 
white blood cells. 
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to provide written confirmation of the patient’s medical 
status with respect to relevant eligibility criteria. This 
will take place prior to the screening visit in order to 
avoid unnecessary visits.
The screening visit will involve documentation of 
written informed consent. Evaluation against trial eligi-
bility criteria will then be performed by individuals who 
are National Health Service employees (substantive or 
honorary) and who have access permissions to examine 
hospital and research databases. Each MS-SMART 
recruiting site will be required to maintain an anony-
mised log of all patients who are ineligible for the trial 
and all eligible patients who will not be randomised 
because they decline participation. This information will 
allow generalisation of the trial results in accordance with 
Consolidated Standards of Reporting Trials (CONSORT) 
reporting guidelines. Prerandomisation tests to be 
performed before a participant can enter the study will 
be detailed. Anonymised information will be collected 
including: age, sex, date of screening, reason not eligible 
to participate (if applicable), reason for declining partici-
pation despite eligibility (if applicable), any other reason 
for non-participation (if applicable).
details of the intervention
Selection of the investigational medicinal products
Systematic review and meta-analysis as previously 
described14 led to our identification of six specific drugs 
(ibudilast, riluzole, amiloride, pirfenidone, fluoxetine 
and oxcarbamazepine) and one drug-class (polyunsat-
urated fatty-acid dietary supplements) as leading candi-
dates for evaluation as repurposed oral neuroprotective 
therapies in SPMS. Based on covering several putative 
mechanisms of action and relative efficacy data, ibudilast, 
riluzole and amiloride were initially selected. However, 
drug supply could not be secured for ibudilast and it was 
therefore replaced by fluoxetine.
Amiloride
It is a widely used diuretic and acid-sensing ion channel 
(ASIC) antagonist, with recently recognised myeloprotec-
tive and neuroprotective effects in experimental models 
of progressive MS.27 2827.28 In an open-label single-arm 
pretest post-test phase IIA clinical trial, 14 patients with 
primary progressive MS (PPMS) were observed for 1 year 
before treatment and after treatment with oral amiloride 
5 mg twice a day. A significant reduction was observed in 
the whole brain atrophy rate compared with pretreat-
ment.29 Amiloride has been used as a potassium-sparing 
diuretic since it was first introduced in 1967 and has an 
extremely good side-effect profile. Although usually 
well tolerated, minor side effects are reported relatively 
frequently. Apart from hyperkalaemia, significant adverse 
reactions have been infrequently reported. Nausea/
anorexia, abdominal pain, flatulence and mild skin rash 
are probably due to amiloride; but other side effects are 
generally associated with diuresis or with the underlying 
disease being treated.
Fluoxetine
It is an SSRI widely used for depression. Multiple actions 
have been described of potential relevance to neuropro-
tection in SPMS such as: stimulating the cAMP-responsive 
element binding protein; increasing the production of 
brain-derived neurotrophic factor and the neurotrophic 
peptide S100beta; enhancing glycogenolysis in astro-
cytes; blocking voltage-gated calcium and sodium chan-
nels and decreasing the conductance of mitochondrial 
voltage-dependent anion channels.30 In pilot clinical 
research, an increase in the cerebral white matter NAA/
creatine ratio has been described suggesting improved 
axonal energy status.31 Recently, results from the Fluox-
etine in Progressive Multiple Sclerosis (FLUOX-PMS) 
study (n=137) showed that there was a trend in favour 
of fluoxetine (p=0.07) on slower progression of disability 
as measured by 25-foot walk test or 9-Hole Peg Test 
(9HPT) after 108 weeks.32 Fluoxetine is usually well 
tolerated, although minor side effects are reported rela-
tively frequently. The most commonly reported adverse 
reactions in patients treated with fluoxetine are head-
ache, nausea, insomnia, fatigue and diarrhoea. Patients 
with a history of suicide-related events, or those exhib-
iting a significant degree of suicidal ideation prior to 
commencement of treatment are known to be at greater 
risk requiring careful monitoring or exclusion from the 
trial.
Riluzole
It is licensed for motor neuron disease/amyotrophic 
lateral sclerosis and has two modes of action relevant to 
SPMS: reducing glutamate release and antagonism of 
voltage-dependent sodium channels.33 A single phase 
IIA clinical trial has been performed in progressive MS; a 
single-arm open-label pretest post-test design involving 16 
participants observed for 1 year before and during treat-
ment with oral riluzole 50 mg twice a day.34 Beneficial 
change was seen in the primary outcome of cervical spine 
cross-sectional area reduction, associated with reduced 
T1 hypointense lesion accumulation and brain atrophy. 
Riluzole is generally well-tolerated at 100 mg/day, with 
the most frequent drug-related events being nausea and 
fatigue. Headache, dizziness, diarrhoea, anorexia and 
paraethesiae are also relatively common. Increased liver 
function tests (LFT) occur in approximately 10% with 
drug withdrawal being required in approximately 4%.
Drug supply and overencapsulation
Amiloride and fluoxetine will be supplied by Actavis UK 
and riluzole will be supplied by Sanofi Genzyme, with 
overencapsulation of active or placebo drug in size 00 
capsules.
Labelling, packaging and storage
Labelling will be blinded in accordance with require-
ments of EU GMP Annex 13. In order to maintain 
blinding, bottles will be coded and both shelf life and 
storage conditions adjusted to maintain blinding. All trial 
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drugs will be packaged in polyethylene bottles containing 
the same number of capsules. Trial drug will be stored 
below 25°C in a dry place and protected from light.
Dispensing, handling and drug accountability
Bottles will be dispensed according to site and study-spe-
cific standard operative procedures (SOPs) by the local 
site pharmacy. A subject-specific accountability log will 
be kept to record each dose of the trial drug dispensed 
for each trial participant. All used returned bottles will be 
kept for potential reconciliation by the sponsor (UCL); 
they will be discarded by the research staff according to 
local procedures, on authorisation from the sponsor.
Dosing regimen
Following randomisation at the baseline visit, study drug 
will be dispensed by the site pharmacy using the following 
dose regimes: amiloride 5 mg once per day for 4 weeks 
and twice per day thereafter; fluoxetine 20 mg once per 
day for 4 weeks and twice per day thereafter; riluzole 
50 mg once per day for 4 weeks and twice per day there-
after; placebo one capsule once per day for 4 weeks and 
twice per day thereafter.
Dose modification and stopping rules
Details on dose modification and stopping rules are 
reported in figure 2.
Evaluation of adherence to study drug
At each visit participants will bring back the unused 
study drug and are asked about adherence. Participants 
will be asked to detail drug adherence over the past 30 
days using a diary card to record the number of capsules 
taken and to indicate any reason for non-adherence. 
Figure 2 Dose modification schema. AE, adverse event; PI, principal investigator; pt, patient.
 o
n
 25 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021944 on 30 August 2018. Downloaded from 
7Connick P, et al. BMJ Open 2018;8:e021944. doi:10.1136/bmjopen-2018-021944
Open access
Adherence will be assessed according to the diary card; 
however, a pill count will also take place. Non-adherence 
to the protocol study procedures will be documented by 
the investigator and reported to the sponsor as required. 
Persistent non-adherence may lead the participant to be 
withdrawn from the study. Follow-up as per the protocol 
is attempted for all non-adherent participants.
Concomitant care and interventions
Based on the three active drugs under investigation, 
the following concomitant medications are absolutely 
contraindicated: lithium, chlorpropamide, potas-
sium supplements, potassium retaining diuretics (eg, 
triamterene, spironolactone), monoamine oxidase 
inhibitors, selective serotonin reuptake inhibitor class 
antidepressants, phenytoin, L-tryptophan, metoprolol 
and neuroleptic drugs. The following should also be 
used with caution: angiotensin-converting inhibitors, 
non-steroidal anti-inflammatory drugs, ciclosporin, 
inhibitors of CYP1A2 (eg, caffeine, diclofenac, diaz-
epam, nicergoline, clomipramine, imipramine, fluvox-
amine, phenacetin, theophylline, amitriptyline and 
quinolones), inducers of CYP1A2 (eg, cigarette smoke, 
charcoal-broiled food, rifampicin and omeprazole), 
St. John’s wort, CYP2D6 isoenzyme inhibitors (eg, 
flecainide, encainide, carbamazepine and tricyclic anti-
depressants) should be initiated at or adjusted to the 
low end of their dose range, drugs that prolong the 
QT interval should be used with caution and care with 
cyproheptadine, drugs inducing hyponatraemia and 
drugs lowering the epileptogenic threshold. If treat-
ment of in-trial depression is needed, the following 
are allowable as they can be safely added to fluoxetine: 
mirtazapine, venlafaxine, duloxetine and agomelatine. 
All other concomitant medications are permitted.
outcomes
Brain imaging will be acquired at baseline, week 24 and 
week 96; clinical efficacy will be measured at baseline, 
week 48 and week 96; safety outcomes will be captured 
at all study visits (table 2)
Primary outcome
The primary outcome measure in MS-SMART will be 
PBVC between baseline and 96 weeks. This metric is 
derived from structural MR brain imaging data using 
the Structural Image Evaluation, using Normalisation of 
Atrophy (SIENA) method,35 part of the Functional MRI 
of the Brain Analysis Group Software Library.36 This 
approach provides a reliable measure of brain atrophy, 
reducing sample size requirements 10-fold compared 
with comparison of absolute volume change measure-
ment.21 Here, brain atrophy is used as a marker of 
neurodegeneration and an interim end point for the 
progression of clinical disability.37 An interim scan at 24 
weeks on-drug will be performed to enable evaluation 
for evidence of pseudoatrophy on active treatment arms 
(see below).
Secondary outcomes; imaging
Count of new and enlarging T2 lesions has proved 
sensitive in detecting the efficacy of immunomodula-
tory drugs to reduce multifocal inflammatory disease 
activity.38 Although new and enlarging T2 lesions appear 
to be less relevant than brain atrophy as a measure of 
neuroprotection in SPMS,39 they are included with brain 
atrophy as a core outcome measure to detect an unan-
ticipated immunomodulatory effect. Rapid resolution 
of inflammation after treatment initiation can result in 
an apparent reduction in brain volume; a phenomenon 
termed pseudoatrophy.40
Secondary outcomes; clinical
MS-SMART captures secondary clinical outcomes that 
reflect the current consensus as codified in two work-
shops held in Washington DC in 2011 and subsequently 
in Rome in 2017, sponsored by the US MS Society and 
European Committee for Treatment and Research 
in MS.23 41While recognising the major challenges of 
measuring disability in a chronic, unpredictable and 
multifaceted disease such as MS, these statements 
provided current expert consensus on approaches to 
MS clinical outcome measurement in trials. We have 
included therefore the: EDSS, MSFC, SDMT, SLCVA, 
MSIS29v2 and MSWSv2. Additional items of interest 
were pain (NPRS, BPI and NPS), fatigue (NFI) and 
health utility data (ED-5D-5L).
Exploratory outcomes
Two exploratory outcomes will be collected in 
MS-SMART, reflecting published recommendations 
following a National MS Society workshop on the 
measurement of neuroprotection in MS.42 (i) The 
proportion of new and enlarging T2 lesions at 24 
weeks being persistently T1 hypointense at 96 weeks. 
Persistently T1 hypointense lesions exhibit greater 
axonal loss43; this measure therefore provides an indi-
cation of the extent of axonal loss associated with new 
inflammatory-demyelinating white matter lesions. (ii) 
Change in brain grey matter volume. This measure has 
demonstrated robust correlations with longitudinal 
change in disability and with cognitive impairment.44
Safety and tolerability outcomes
All study visits will capture data on intervening MS 
relapses and adverse events (AEs). In addition, blood 
monitoring will be performed to evaluate renal func-
tion (serum creatinine), electrolytes, liver function 
(bilirubin, transaminases and gamma glutamyl trans-
ferase [gamma-GT]) and haematological parameters 
(haemoglobin concentration, white blood cell and 
platelet counts).
sample size
A total of 440 patients will be randomised equally 
(1:1:1:1) between the three active treatments and the 
placebo. The primary analysis is intention-to-treat on 
the whole study cohort. Based on two UK phase II trials 
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(lamotrigine45 and MS-STAT),22 we expect 10% of the 
total cohort to drop out of the trial before year 2, and 
a further 10% of the total cohort to come for their year 
2 visit, but be off medication. We anticipate therefore 
about 90 patients/arm completing the study. From the 
calculations reported by Altmann et al for measurement 
of PBVC using the SIENA registration-based method,21 
90 patients per arm would give over 90% power to detect 
a 40% reduction in PBVC on any active arm compared 
with placebo and 80% power to detect a 35% reduction, 
analysing by analysis of covariance and with Bonferroni 
adjustment for multiple comparisons of three 1.67% 
two-sided tests, giving a 5% overall two-sided signifi-
cance level (table 3). For a more exploratory analysis 
without adjusting for multiple comparisons, this sample 
size will give almost 90% power to detect a 35% reduc-
tion in atrophy. MS-SMART is not powered to detect 
differences between the three active treatment arms.
AssIgnMEnt of IntErvEntIons
treatment allocation
Randomisation (1:1:1:1) will be performed by the 
research nurse via a secure web-based service provided 
by the Edinburgh Clinical Trials Unit (ECTU). The 
following minimisation variables will be used: sex, age 
(<45 years; 45 years or more), baseline EDSS (4.0–5.5; 
6.0–6.5), trial site. The minimisation algorithm will incor-
porate a random element to maintain unpredictability of 
treatment allocation.
blinding
Investigators and participants will be blinded to the treat-
ment allocation. The following measures will be taken to 
ensure blinding: (i) amiloride, fluoxetine and riluzole are 
overencapsulated so that they are identical in appearance 
to one another and to placebo. (ii) The same number of 
capsules will be prescribed for participants in each arm. 
(iii) The drugs supplied from the manufacturers will be 
repackaged by an organisation independent of the trial 
and the same organisation supplies pharmacies at partici-
pating sites directly with the trial drugs. (iv) Drug supplies 
to pharmacies will be coded. (v) The randomisation list 
will be held by the ECTU to ensure that treatment allo-
cation is concealed from the investigator’s team and the 
participant, while providing provisions for emergency 
unblinding.
dAtA CollECtIon, MAnAgEMEnt And AnAlysIs
Clinical data collection and management
All clinical data will be collected by staff whose compe-
tence to perform their specific role(s) has been recorded 
in the delegation log and approved by the site PI. Local 
research staff will enter data onto an electronic case 
report file (eCRF) via a secure, web-based portal. Access 
is password protected and limited to nominated staff as 
recorded on the delegation log. Members of staff will be 
identifiable by a unique username and password. Site 
staff will be responsible for recording full and accurate 
data onto the database. Only anonymised data will be 
recorded on trial paperwork and the eCRF. Designated 
staff at ECTU will follow SOPs to obtain missing data and 
resolve queries with site staff and to ensure data quality 
and completeness of data across sites. The trial database 
includes in-built systems to ensure the validity and quality 
of the data, and to generate queries. Cross-validation is 
employed and data entry is a single entry.
Trial data will be held on a secure server at ECTU, data 
will be stored on a secure server according to ECTU stan-
dard operating procedures. All transfer of data will be in 
accordance with the Data Protection Act 1998 and the 
UCL Information Security Policy and Trust Information 
Governance Policy.
Imaging data acquisiiton, quality control and image analysis 
methods
The following MRI sequences will be obtained at all three 
MR assessment visits for all participants: (i) Sagittal local-
iser to identify the subcallosal line. (ii) Axial dual echo 
fast/turbo spin echo proton density (PD)/T2 weighted 
from foramen magnum to vertex with no gap, in plane 
resolution 1 mm2, slice thickness 3 mm. (iii) Axial fluid 
attenuated inversion recovery from foramen magnum to 
vertex with no gap, in plane resolution 1 mm2, slice thick-
ness 3 mm. (iv) Axial T1 from foramen magnum to vertex 
with no gap, in plane resolution 1 mm2, slice thickness 
3 mm. (v) Sagittal three-dimensional (3D) T1 gradient 
echo with voxel resolution of 1 mm3. Initial sequence 
parameters will be proposed (table 4). The core MRI 
scannig protocol will take  25  min. Final parameters for 
each site will be agreed between the central MRI facility 
(Queen Square MS Centre, London) and the local MR 
team based on provision of a ‘dummy scan’ (healthy 
volunteer or a person with MS) before trial commence-
ment. Quality control feedback will be generated by 
review at the central MRI facility soon after scan acquisi-
tion and provided to the site.
Table 3 MS-SMART required sample size/arm by treatment 
effect size, significance level and statistical power
MRI measurement times Baseline–96 weeks
Two-sided significance level 0.0167 0.05
Statistical power (%) 80 90 80 90
Treatment effect: 123 158 92 123
  30% 
  35% 90 116 68 91
  40% 69 89 52 70
Treatment effect will be expressed as relative mean difference 
in PBVC under treatment. PBVC assessed using the SIENA 
registration-based method.
MS-SMART, Multiple Sclerosis-Secondary Progressive Multi-Arm 
Randomisation Trial; PBVC, percentage of brain volume change; 
SIENA, Structural Image Evaluation, using Normalisation of 
Atrophy. 
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PBVC will be quantified using the SIENA method as 
previously described. Briefly, on receipt of DICOM images 
to the central MRI facility and after quality control, the T2 
lesions will be outlined on PD scans by trained personnel 
blinded to clinical data using a semi-automatic method 
(Jim 7 Software, Xinapse Systems, UK). On further MS 
expert review, T2 lesion masks will be used to fill the 
3D T1-weighed images and, from these, brains will be 
extracted using the geodesic information flows algorithm 
(TIG, UCL http:// cmictig. cs. ucl. ac. uk/ niftyweb).46 
Finally, the SIENA method will be applied to the 3D T1 
image and the segmentation to produce a percentage 
change in brain volume between baseline and week 96 
scans.
Table 4 Guide to MS-SMART MRI scan parameters for use as reference in dummy run scan for each site according to 
scanner model
Scan
Dual echo PD/T2-
weighted FSE/TSE T2-weighted FLAIR T1-weighted SE
3D T1-weighted 
volumetric MPRAGE/
IRFSPGR/TFE
Slice orientation Axial-oblique Axial-oblique Axial-oblique Sagittal-oblique
First TE Siemens 1.5 T/3 T 11/26 ms 122/100 ms 12/6.8 ms 3.45/4 ms
First TE GE 1.5 T/3 T 21/24 ms 128/127 ms 20/20 ms 5/3 ms
First TE Philips 1.5 T/3 T 16/13 ms 120/120 ms 20/10 ms 4/3.2 ms
Second TE Siemens 1.5 T/3 T 86/97 ms NA NA NA
SecondTE GE 1.5 T/3 T 86/85 ms
Second TE Philips 1.5 T/3 T 100/90 ms
TR Siemens 1.5 T/3 T 2680/2700 ms 9500/9500 ms 518/600 ms 2400/2400 ms
TR GE 1.5 T/3 T 2900/2600 ms 10000/9500 ms 650/700 ms 13/8 ms
TR Philips 1.5 T/3 T 3300/2900 ms 10000/9500 ms 600/600 ms 12/6.9 ms
TI Siemens 1.5 T/3 T NA 2400/2400 ms NA 1000/1000 ms
GE 1.5 T/3 T 2200/2400 ms 650/450 ms
Philips 1.5 T/3 T 2400/2400 ms 950/830 ms
Number of slices ≥46 ≥46 ≥46 ≥176
Slice thickness 3 mm 3 mm 3 mm 1 mm
Slice gap 0 mm 0 mm 0 mm 0 mm
Echo train length Siemens 1.5 
T/3 T
7/5 19/15 NA NA
Echo train length GE 1.5 T/3 T 10/8 19/19
Echo train length Philips 1.5 T/3 T 5/6 19/19
Field of view 25 cmx100% 25 cmx100% 25 cmx100% 25 cmx100%
Image matrix acquisition 256×256 256×192 256×256 256×256
(frequency×phase)
Image matrix reconstruction 256×256 256×256 256×256 256×256
(frequency×phase)
Reconstructed pixel size 0.976 0.976 0.976 0.976
Frequency encoding a/p a/p a/p s/i
Phase encoding r/l r/l r/l a/p
No. of averages (excitations) 1.5 
T/3 T
1 January 1 January 1 February 1 January
Flip angle Siemens – – – 8°
Flip angle GE 20°
Flip angle Philips 8°
Reference parameters guidance depending on scanner model (ie, Siemens, Philips, GE) and operating field strength (ie, 1.5 T or 3 T). The 
values listed in bold are mandatory for all of the sites.
a/p, anterior/posterior; FLAIR, fluid attenuated inversion recovery; FSE/TSE, fast/turbo spin echo; IRFSPGR, inversion recovery fast spoiled 
gradient echo; MPRAGE, magnetisation prepared rapid gradient echo; NA, not applicable; r/l, right/left; SE, spin echo; s/i, superior/inferior; 
TFE, turbo field echo.
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statistical methods
Descriptive statistics
A CONSORT flow diagram will be reported. Exploratory 
summary methods will be used to describe baseline 
characteristics: continuous variables will be summarised 
using summary statistics (mean, SD, median, IQR, 
minimum and maximum) by treatment group, and 
categorical variables will be presented using frequen-
cies and percentages by treatment group. Proportions 
of patients with missing 96 week MRI data in each treat-
ment group will also be summarised, as will baseline 
data for patients with missing and non-missing 96-week 
follow-up data.
Primary MRI outcome measure
A normal linear model will be used to compare each 
of the three active treatment group arms with placebo, 
adjusting for baseline normalised brain volume (BNBV) 
and minimisation variables: age, gender, treatment centre 
(as a fixed effect) and baseline EDSS. Baseline BNBV will 
be entered into the model as a continuous variable, as 
will age and baseline EDSS. Other minimisation variables 
will be included in the models according to the catego-
ries used in the randomisation; if there are fewer than 
ten patients in any category, categories will be combined 
where possible. The efficacy measure for each active treat-
ment will be the mean difference in PBVC change versus 
placebo. All patients for whom baseline and 96-week brain 
volume data are available will be included in the analysis 
according to the treatment group to which they were 
randomised irrespective of which treatment(s) they may 
have received. Dunnett’s method will be used to adjust 
for the multiple pairwise comparisons versus a common 
placebo group. No formal comparisons of the active treat-
ments will be undertaken. The primary analysis will be 
on complete cases. Three sensitivity analyses, based on 
pattern mixture modelling, standard multiple imputa-
tion and exclusion of extreme outliers on the primary 
outcome will be used to explore the effect of missing data 
on the primary outcome analysis.
Counts of new and enlarging T2 lesions
Each active treatment group will be compared with 
placebo for the number of new and enlarging T2 lesions 
between the baseline and 96 week MRI. Overdispersed 
Poisson regression models will be used to estimate a rate 
ratio for each comparison after adjusting for baseline T2 
lesion volume and the minimsation variables: age, gender, 
treatment centre and baseline EDSS.
Pseudoatrophy
Using the same methods as for the primary MRI outcome 
analysis, the mean difference in PBVC from baseline to 6 
months between the placebo group and each of the active 
treatment groups will also be assessed. If the reduction 
in PBVC is significantly greater in any treatment group 
a secondary analysis will compare PBVC from week 24 to 
week 96 between that treatment group and the placebo 
group using normal linear modelling as described for the 
primary outcome measure.
Clinical secondary outcome measures
If the change over time in continuous outcomes (EDSS, 
9HPT, PASAT, MSFC, SDMT, SLCVA, MSIS29v2, MSWSv2, 
NFI, NPRS, NPS, BPI and EQ-5D-5L) is found to be 
reasonably normally distributed, following transforma-
tion where necessary, comparison will be made between 
active treatments and the placebo group using normal 
linear models as for the primary outcome measure. If 
normality cannot be assumed, an unadjusted non-para-
metric Mann-Whitney U test will be used to compare each 
active treatment to placebo. For NPS, the same method 
will be used as for the other continuous outcome, but 
applied to the individual questionnaire items, with the 
exception of the components of item 8, which will be anal-
ysed using logistic regression. Cox proportional hazard 
models (adjusting for the minimisation variables) will 
be used for time to first relapse and timed 25 foot walk, 
with the difference between each active treatment and 
placebo being expressed in terms of an HR. In explor-
atory analyses, additional statistical modelling will assess 
whether composites of imaging and disability measures 
at baseline can be used to predict temporal evolution 
of SPMS and response to treatment. The proportion of 
participants with an increase in EDSS score of at least 1.0 
at 96 weeks relative to baseline will be analysed using a 
multiple logistic regression model adjusting for the mini-
misation variables.
MonItorIng
data monitoring
An independent Data Monitoring Committee (DMC) will 
be established to oversee the safety of participants in the 
trial. The terms of reference of the DMC will be docu-
mented in a charter that will be held in the Trial Master 
File (TMF) at ECTU. Unblinded safety data will be moni-
tored by the DMC to ensure the ongoing safety of patients 
in the study. Stopping criteria are not prespecified to the 
DMC and no formal interim analyses will be planned. A 
Trial Steering Committee (TSC) will be established to 
oversee the conduct and progress of the trial. The terms 
of reference of the TSC will be documented in a charter 
that will be held in the TMF at ECTU.
harms
Detection, recording and reporting of adverse events
All AEs will be recorded in the medical records from the 
time a participant signs the consent form to take part 
in the study until study exit (week 100). Participants 
will be asked about the occurrence of AEs or serious 
adverse events (SAEs) at every visit during the study. 
Open-ended and non-leading verbal questioning of 
the participant will be used to enquire about AE/SAE 
occurrence. Participants will also be asked if they have 
been admitted to hospital, had any accidents, used any 
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new medicines or changed concomitant medication 
regimens. AE data will also be available from informa-
tion written by the participant on the participant diary, 
and from laboratory results. Progressive change due to 
SPMS, in motor, sensory, balance, sphincter (including 
urinary tract infections), vision, cognitive and fatigue 
levels will be excluded as AEs/SAEs/Serious Adverse 
Reactions (SARs) and are not reported as such. In addi-
tion, relapses will not be counted as AEs/SAEs/SARs, but 
will be collated separately.
Reporting to the sponsor will be completed as per the 
sponsor’s SOP and using the UCL SAE forms (INV/S05). 
The AE log will be reported to the sponsor at least once 
per year. All SAEs will be reported to the sponsor on a 
SAE form by the chief investigator (CI) or site PI within 
24 hours of them becoming aware of the event. A copy 
will be also sent in tandem to the ECTU for notification. 
All Suspected Unexpected Serious Adverse Reactions 
(SUSARs) will be notified to the sponsor immediately (or 
at least within 24 hours). The sponsor will notify the main 
Research Ethics Committee (REC) and Medicines Health-
care products Regulatory Agency (MHRA) of all SUSARs. 
SUSARs that are fatal or life-threatening will be notified 
to the MHRA and REC within 7 days after the sponsor 
has learnt of them. Other SUSARs will be reported to the 
REC and MHRA within 15 days.
Management of laboratory abnormalities
Clinical biochemistry
If serum potassium is <2.8 or >5.5 mmol/L, or if serum 
sodium is <125 mmol/L, study drug will be suspended 
and electrolytes measured at 2–4 weeks. If normalised, 
treatment will be recommenced. If not normalised, 
treatment will be suspended for a further 2–4 weeks. If 
abnormality persists at this stage, treatment will be discon-
tinued. If creatinine >130 µmol/L, confirmatory bloods 
are performed within a week. If abnormalities persist, 
study drug will be reduced to ‘half dose’ if taking medica-
tion twice a day (ie, ‘full dose’) or stopped if taking ‘half 
dose’. Repeat measurement will be undertaken at 2–4 
weeks. If parameters have normalised, rechallenge will 
be considered. Derangement of liver function tests where 
alanine aminotransferase (ALT) or aspartate aminotrans-
ferase (AST) or bilirubin or gamma-GT <3 times the 
upper limit of normal (ULN), commencement, continu-
ation or advancement of placebo/investigational medical 
product (IMP) will continue as previously planned. If LFT 
measures are >3 times the ULN, confirmation by repeat 
measurement will be performed within a week. If abnor-
malities persist the study drug will be reduced to ‘half 
dose’ if taking medication twice a day (ie, ‘full dose’) or 
stopped if taking ‘half dose’. Repeat measurement will be 
undertaken at 2–4 weeks. If parameters have normalised, 
rechallenge will be considered. If ALT or AST or bili-
rubin or gamma-GT >5 times the ULN, study drug will be 
discontinued.
Clinical haematology
If haemoglobin remains <80 g/L, study drug will be 
suspended and local protocols should be followed to 
investigate anaemia. If haemoglobin improves towards 
baseline at 2–4 weeks, rechallenge will be considered. If 
haemoglobin remains <80 g/L treatment will be discon-
tinued. If neutrophil count reduces to <1.0×109/L or 
platelet count to <50×109/L, study drug will be suspended. 
If parameters normalised at 2–4 weeks, rechallenge will 
be considered. Study drug will be discontinued if param-
eters remain below these levels.
Emergency unblinding procedures
Randomised participants will be given a card to indicate 
they are on the trial with the emergency contact numbers 
for medical advice including unblinding. Participants will 
be instructed to show this card to any healthcare profes-
sional involved in their care who will be not involved in 
the trial. Unblinding may take place in situations where 
the safe management of the participant’s medical condi-
tion necessitates knowledge of the study medication by the 
person(s) responsible for the participant’s care. Where 
possible, members of the local research team will remain 
blinded. If unblinding is required the local PI/other 
medical staff will use a 24 hours emergency telephone 
contact as provided on the participant’s card. The person 
requesting unblinding will provide details including the 
protocol number and trial name, name of the requester, 
reason for unblinding, patient name, participant number 
and timeline to receive the unblinded information. If 
knowledge of the treatment allocation is required in order 
to treat the patient, the code break number will be given to 
the local PI/other medical staff requesting to unblind the 
patient. The local PI/other medical staff can then use the 
code break number to reveal the participants treatment 
allocation. In this way, the treatment will be unblinded at 
the local site but not to the ECTU member of staff or CIs.
Withdrawal of study participants and early termination of the trial
Trial participants will be free to withdraw from the trial 
at any point or can be withdrawn by the investigator. If 
withdrawal occurs, the primary reason for withdrawal 
will be documented in the participant’s CRF. Trial partic-
ipant withdrawals will not be replaced. If a participant 
discontinues study drug, this will not necessarily consti-
tute withdrawal from the trial: in this case, all attempts 
will be made to follow-up the participant as per protocol 
and to recommence treatment. The DMC will be able to 
recommend trial or trial arm suspension/termination, 
according to the terms of the DMC charter, for example, 
due to unacceptable AEs.
Auditing
A trial-specific monitoring plan will be established in 
accordance with the sponsor’s SOPs. An appointed 
monitor will visit the Investigator site prior to the start of 
the study and during the course of the study and in accor-
dance with the predefined monitoring plan.
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PAtIEnt PublIC InvolvEMEnt
Patient public involvement (PPI) has been a vital 
part of the evolution of the study, both through the 
MS CTN, which includes patient representation, 
and directly through a specifically convened focus 
group which enabled patients with SPMS to provide 
constructive feedback on the design of the study. Our 
PPI representative will be an integral member of the 
MS-SMART team and will sit on the Study Manage-
ment Group—ensuring PPI is at the heart of our 
research and making certain there are meaningful 
links with and between service providers, users and 
methodologists. MS-SMART was highlighted in the 
UK MS Society Patient Conference, MS Life 2012. 
We identified the training and support needs of 
PPI members (and researchers in relation to PPI) 
and provided appropriate support and training. PPI 
members will be mentored by members of the trial 
team. The mentorship role will provide research and 
personal support to PPI members before and after 
meetings, addressing queries about the research 
process, language and documentation. We will adhere 
to INVOLVE guidelines for involving the public in 
research and reimburse PPI members in accordance 
with INVOLVE rates. Suggestions from our PPI group 
were used to inform the design of the research. 
Specifically: 1) the group emphasised the importance 
of working with early SPMS patients (EDSS scores 
<6.5) prior to the ambulatory phase in light that any 
neuroprotective drug is likely to have most benefit; 2) 
a multiarm design was preferable to standard single 
arm versus placebo to ensure that a maximum number 
of patients would have access to putative neuroprotec-
tive repurposed drugs compared with placebo; 3) they 
considered that the burden of advanced MRI protocol 
was acceptable to patients in view of the potential 
advancement that will come from the imaging analysis 
to the mechanistic elucidation—all their recommen-
dations were taken on board. The scientific approach 
in MS-SMART was recognised as being completely in 
tune with what those with SPMS wanted. The results 
of the study will ultimately be given individually (via 
email) to those who have taken part.
EthICs And dIssEMInAtIon
Protocol amendments
There have been five substantial protocol amendments 
and these are listed in table 5.
Informed consent
All MS-SMART participants will be required to provide 
written informed consent before any protocol-specific 
procedures are carried out according to the principle of 
Good Clinical Practice. The participant will agree to their 
medical records being inspected by regulatory authorities 
and representatives of the sponsor(s).
Confidentiality
All laboratory specimens, evaluation forms, reports and 
other records will be identified in a manner designed 
to maintain participant confidentiality. All records will 
be kept in a secure storage area with limited access. 
Clinical information will not be released without the 
written permission of the participant. The Investi-
gator and study site staff involved with this study may 
not disclose or use for any purpose other than perfor-
mance of the study, any data, record or other unpub-
lished, confidential information disclosed to those 
individuals for the purpose of the study. Prior written 
agreement from the sponsor or its designee must be 
obtained for the disclosure of any said confidential 
information to other parties. The CRFs will not bear 
Table 5 Protocol amendments
Protocol update Protocol version Protocol date Reason for amendment
NA V1 1 January 2013 NA
Substantial amendment V1 1 January 2013 Addition of new sites.
Substantial amendment V2*
V3
1 December 2013 
1 June 2014
See note below.
Replacement of the drug ibudilast with fluoxetine.
Substantial amendment V4 25 May 2015 Change to eligibility criteria to exclude patients 
on high-dose simvastatin. Clarification in patient 
information sheet about side effects of fluoxetine.
Substantial amendment V5 1 November 2016 Protocol updated to reflect changes to fluoxetine 
summary of product characteristics.
Non-substantial amendment V6 5 October 2017 To update new trials unit address and telephone 
numbers.
Substantial amendment V6 5 October 2017 To update change of PI.
Non-substantial amendment V7 4 June 2018 To correct typing error of ClinGov number.
*Protocol V.2 was submitted for the Clinical Trial Authorisation.
NA, not applicable.
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the subject’s name or other personal identifiable data 
other than the subject’s initials and date of birth.
Access to data
The CIs will have full access to the final data set, following 
completion of the main trial analysis by study statisticians. 
Prior to publication of the main findings of MS-SMART, 
additional plans by the UCL or ECTU trial teams to analyse 
MS-SMART data must be approved by the CI and trial stat-
istician, with any resulting published outputs, requiring 
approval from the DMC, TSC and writing committee. 
Requests for use of MS-SMART data from other collabo-
rators or external parties will require approval from the 
DMC Chair, TSC Chair and writing committee.
Ancillary and post-trial care
Routine clinical care will continue to be provided by 
treating neurologists throughout the duration of the trial 
and following its completion.
dissemination policy
MS-SMART is listed on three publicly accessible registries: 
clinicaltrials. gov (NCT01910259);  clin ical tria lsre gister. eu 
(2012-005394-31);  isrctn. com (ISRCTN28440672).
To maintain the scientific integrity of the study, data 
will not be released prior to the first publication of the 
results of the primary end point analysis, either for study 
publication or oral presentation purposes, without the 
permission of the DMC and the TSC. The TSC will agree 
a publication plan and must be consulted prior to release 
or publication of any study data. All proposed publica-
tions and presentations will be discussed with the sponsor, 
co-CIs and ECTU prior to their release. The clinical trial 
report will be used for publication and presentation at 
scientific meetings. Summaries of results will also be 
made available to investigators for dissemination within 
their clinics (where appropriate and at their discretion). 
Credit for the main results will be given to all those who 
have collaborated in the study, through authorship and 
by contribution. Uniform requirements for authorship 
for manuscripts submitted to medical journals will guide 
authorship decisions (www. icmje. org).
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